NCT01238952已完成1 期
A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Triple Negative Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose
研究概览
简要总结
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.
详细描述
NK012 will be administered as a 30 minute IV infusion, followed by a 30 minute carboplatin IV infusion. Both drugs will be administered once every 28 days. Treatment is expected to continue for 6 cycles, unless disease progression or the development of unacceptable toxicity requires discontinuation of the drug. At the discretion of the investigator, patients who show signs of benefit may continue beyond 6 cycles.
Once a MTD/RD has been determined, a dose expansion cohort of patients with metastatic triple negative breast cancer will be treated at the determined MTD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced solid tumor for which no efficacious therapy exists, or for which a camptothecin-based regimen would be appropriate.
- •For the dose expansion at the MTD/RD only:
- •Patients must have triple-negative breast cancer with locally advanced disease for which there is no surgical option, or stage IV disease. Triple-negative breast cancer is defined as HER2-negative, ER-negative, and PR-negative as follows:
- •For HER2- negative (must meet one of the following 3):
- •( i) FISH negative (ratio <2.2); or ( ii) IHC 0 or 1+; or (iii) IHC 2+ or 3+ and FISH negative (ratio <2.2) For ER negative and PR negative: ≤ 10% tumor staining by IHC
- •No less than one and no more than two prior chemotherapy regimens for advanced or metastatic breast cancer.
- •Patients must have measurable disease by RECIST (version 1.1).
- •Patients must have recovered from all acute adverse effects of prior therapies, excluding alopecia.
- •For patients enrolled in the dose escalation phase, no more than 4 prior cytotoxic regimens in the metastatic setting.
- •Prior irradiation to no more than 25% of the bone marrow.
- •ECOG performance status of 0 or
- •Life expectancy of at least 12 weeks.
- •Patients are at least 18 years of age.
- •Adequate bone marrow function defined as ANC ≥ 1500/mm^3 and platelet count ≥ 100,000/mm^
- •AST and ALT ≤ 3.0 x ULN (5X ULN if documented liver metastases) and total bilirubin ≤ 1.5 x ULN.
- •Serum creatinine < 1.5 x ULN, or creatinine clearance > 60 mL/min by Cockcroft-Gault formula* for patients with serum creatinine > 1.5x ULN.
- •* Cockcroft-Gault formula for creatinine clearance (CrCl): Males: CrCl (ml/min) = (140 - age) x wt (kg) / (serum creatinine x 72) Females: Multiply the above result by 0.85
- •Able to understand and show willingness to sign a written informed consent document.
排除标准
- •Prior chemotherapy, radiation therapy, or investigational therapy within 4 weeks (exception: 6 weeks for nitrosoureas or mitomycin C); or prior non-cytotoxic therapy within 5 drug half-lives (or 4 weeks, which ever is shorter); or monoclonal antibodies within 4 weeks prior to the first dose of study treatment.
- •Concurrent use of another investigational agent.
- •History of brain metastases or spinal cord compression, unless irradiated or treated a minimum of 4 weeks prior to first study treatment and stable without requirement of corticosteroids for > 1 week.
- •Concurrent serious infections requiring parenteral antibiotic therapy.
- •Pregnant or of childbearing potential and not using methods to avoid pregnancy. A negative pregnancy test must be documented at baseline for women of child-bearing potential. Patients may not breast feed infants while on this study.
- •Significant cardiac disease including heart failure that meets NYHA class III and IV definitions, history of myocardial infarction within 6 months of study entry, uncontrolled dysrhythmias or poorly controlled angina.
- •History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row), QTc ≥ 450 msec for men and 470 msec for women, or LVEF ≤ 40% by MUGA or ECHO.
- •History of allergic reactions attributed to compounds of topoisomerase I inhibitors, or platinum-containing compounds.
- •Prior treatment with irinotecan.
- •Prior treatment with more than 6 cycles of platinum drugs.
结局指标
主要结局
Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose
时间窗: From date of first dose to off-study (or 30 days since last dose)
次要结局
- Peak Plasma Concentration (Cmax) of NK012 and carboplatin(15,30,60min,1,6,24,48,50,72hrs,1,2,3,4wk)
- Tumor measurements, as a measure of efficacy(Baseline, then on average every 2 months until off-study)
- Area under the plasma concentration versus time curve (AUC) of NK012 and carboplatin(15,30,60min,1,6,24,48,50,72hrs,1,2,3,4wk)
- Number of patients with adverse events as a measure of safety and tolerability(From date of first dose to off-study (or 30 days since last dose))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal CancerAdvanced Solid TumorsMetastatic Colorectal CancerNCT01238939Nippon Kayaku Co., Ltd.35
已完成
1 期
Study of NK012 in Patients With Refractory Solid TumorsCancerNCT00542958Nippon Kayaku Co., Ltd.39
已完成
1 期
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological CancerHematological MalignanciesNCT01607892Karyopharm Therapeutics Inc286
终止
1 期
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)Advanced Solid TumorsBreast CancerNCT00963547Merck Sharp & Dohme LLC33
招募中
1 期
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung CancerRecurrent Extensive Stage Small Cell Lung CarcinomaNCT05728619Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.64